INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $18,935,000 | +9.2% | 21,504,000 | 0.0% | 0.21% | +32.5% |
| Q1 2018 | $17,338,000 | -48.7% | 21,504,000 | -49.1% | 0.16% | -44.1% |
| Q4 2017 | $33,828,000 | -39.8% | 42,285,000 | -41.5% | 0.28% | -41.9% |
| Q3 2017 | $56,202,000 | -21.3% | 72,285,000 | -1.0% | 0.48% | -8.5% |
| Q2 2017 | $71,392,000 | +4.3% | 73,035,000 | 0.0% | 0.53% | -16.6% |
| Q1 2017 | $68,425,000 | +5.1% | 73,035,000 | 0.0% | 0.63% | +17.4% |
| Q4 2016 | $65,092,000 | +152.0% | 73,035,000 | +217.5% | 0.54% | +123.1% |
| Q3 2016 | $25,832,000 | – | 23,000,000 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERBACK ASSET MANAGEMENT LLC | 12,851,000 | $12,016,000 | 2.95% |
| Context Capital Management, LLC | 3,000,000 | $2,804,000 | 2.24% |
| Man Investments (CH) AG | 3,000,000 | $2,798,000 | 1.76% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 42,500,000 | $39,540,000 | 1.52% |
| MACKAY SHIELDS LLC | 17,069,000 | $15,982,000 | 0.73% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 73,035,000 | $68,425,000 | 0.63% |
| WOLVERINE ASSET MANAGEMENT LLC | 42,307,000 | $39,554,000 | 0.61% |
| LINDEN ADVISORS LP | 14,122,000 | $13,194,000 | 0.49% |
| GLG LLC | 9,100,000 | $8,486,000 | 0.47% |
| Jabre Capital Partners S.A. | 3,400,000 | $3,179,000 | 0.38% |